Retinal vein occlusion

The PBS subsidises aflibercept and ranibizumab for patients with branched retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO), with macular oedema.

Aflibercept and ranibizumab can be subsidised through the PBS under section 85 of the National Health Act 1953 for patients with retinal vein occlusion with macular oedema.

Patient eligibility

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing aflibercept and ranibizumab.

Patients must be treated by an ophthalmologist to be eligible for PBS subsidised treatment with these medications.

Applications

Initial treatment

Make all initial applications for authority approval to prescribe aflibercept and ranibizumab for the treatment of retinal vein occlusion with macular oedema in writing and:

All applications must include:

Continuing treatment

You can make an application for continuing treatment by calling the PBS Complex Drugs Programs enquiry line.

Emergency treatments only

To avoid a delay in starting treatment, you can fax the completed authority application form, authority prescription form and any relevant attachments to the PBS Complex Drugs Programs team, who will contact the prescriber by phone. You are no longer required to send the original authority prescriptions form, authority application form and any relevant attachments.

Further information

For more information call the PBS Complex Drugs Programs enquiry line.

Page last updated: 1 October 2017